NIKKEI 225
38,274.05 -131.61 (-0.34%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
79.20 -2.73 (-3.33%) GOLD FUTURES
2,311.80 +8.90 (+0.39%) DOW
37,969.27 +153.35 (+0.41%) Bitcoin GBP
45,813.66 -2,457.34 (-5.09%)
Teleflex Incorporated (TBH.F)
| Previous close | 191.00 |
| Open | 192.00 |
| Bid | 195.00 x 10000 |
| Ask | 197.00 x 10000 |
| Day's range | 192.00 - 192.00 |
| 52-week range | 167.00 - 242.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 9.176B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 27.23 |
| EPS (TTM) | 7.05 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 1.25 (0.65%) |
| Ex-dividend date | 29 Feb 2024 |
| 1y target est | 462.55 |
ZacksWill These 5 MedTech Stocks Beat Forecasts This Earnings Season?
Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.
ZacksAhead of Teleflex (TFX) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Teleflex (TFX) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
GlobeNewswireTeleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) -Additional studies examine post-surgery medication use, rates of hospitalization and adverse events of standard BPH treatments -Teleflex unveils latest advancements in BPH treatment with UroLift™ 2 System with Advanced Tissue Control (ATC) designed to treat all prostate types - WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Tel
